- Chris Morris
- Jun 14, 2017
- 333 Views
A new drug manufactured by AbbVie has successfully passed through its primary and secondary targets on the way to being fully approved.
Upadacitinib treats rheumatoid arthritis, and the late-stage trial of the medicine has been passed adequately.
The Phase III clinical trial evaluated the investigational oral JAK1-selective inhibitor in patients with the condition who did not adequately respond to treatment with conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs).
After 12 weeks of treatment, data indicated that doses of the drug met the study’s primary endpoints of ACR20 and low disease activity.
Meanwhile, key secondary endpoints were also achieved, which included ACR50, ACR70 and clinical remission.
Results indicated an approximately 65% improvement when taking a 50mg or 30mg daily dose of upadacitinib.
And low disease activity was achieved by 48% of patients receiving either dose of AbbVie’s drug, while clinical decommissioning was achieved by 31%.
“Selective inhibition of the JAK1 pathway may offer a novel treatment for rheumatoid arthritis patients who do not adequately respond to conventional therapies. We are especially encouraged by the results on the more stringent measures of efficacy, such as ACR70, low disease activity and clinical remission,” Michael Severino, AbbVie’s executive vice president, R&D, and chief scientific officer, commented.
Full results will be presented at an upcoming medical meeting and published in a peer-reviewed publication, according to AbbVie.
AbbVie discovers, develops and markets both biopharmaceuticals and small molecule drugs.
It originated in 2013 as a spin-off of Abbott Laboratories, and accumulated over $25 billion of revenue in 2016.